Arresto lands funds to treat cancer and fibrotic disease
Arresto Biosciences, maker of a drug that targets both cancer and fibrotic diseases, just landed an undisclosed third round of funding to push its lead compound closer to clinical trials. The Palo Alto, Calif. company is taking a new approach to the destruction of tumors. Instead of killing their cells directly, its drug would eliminate elements of the host environment that tumors need to metastasize and survive. This could prove helpful at extremely early or late stages of the disease in question, Arresto told VentureWire.
The recent round of investment was led by Northgate Capital and included DAG Ventures, HealthCare Ventures and Kleiner Perkins Caufield & Byers. Company representatives say the amount provided should last for about two years.
Next Story: Apex Construction cobbles together funds for green building blocks
Previous Story: Act Solar awaits $9M to boost energy generation
About the Author, Camille Ricketts
Camille is the lead writer for GreenBeat. She came to VentureBeat from Google where she worked on its traditional platforms team, particularly in TV. Before that, she was a reporter for the Wall Street Journal in New York and London. Follow her on Twitter at @camillericketts, and follow VentureBeat on Twitter at @venturebeat.
With GreenBeat 2009, VentureBeat's all-star conference on all things Smart Grid, coming up in November, Camille will be expanding coverage of this exciting space. Stay up to date by following @greenbeat2009 on Twitter or by becoming a fan of the event on Facebook here.